GT Biopharma (GTBP) Enrolls Patient 10 in GTB-3550 TriKE Phase I/II Clinical Trial

April 8, 2021 8:01 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

GT Biopharma, Inc. (NASDAQ: GTBP) announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). Patient 10 will be dosed at 100mcg/kg/day.

Highlights from the first nine patients treated with GTB-3550 TriKE™ include:

  • Up to 63.7% Reduction in Bone Marrow Blast Levels
  • Restores Patient's Endogenous NK Cell Function, Proliferation and Immune Surveillance
  • No Progenitor-derived or Autologous/Allogenic Cell Therapy Required
  • No Cytokine Release Syndrome Observed
  • 3 out of the Last 5 Patients Treated (25mcg/kg/day to 100mcg/kg/day) Respond

"We are pleased with the continued clinical performance of our lead TriKE™ product candidate, and in reaching this important patient enrollment milestone," said Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer. "The data from the first nine patients treated with GTB-3550 indicates significant bone marrow blast level reductions in AML and MDS patients without the need for expensive progenitor-derived or autologous/allogenic cell therapies."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities

Definitive Agreement, FDA